These Stocks Are Today’s Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and...

These Stocks Are Today’s Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More  Barron's

Novo 'wishes Pfizer luck' with Metsera drug, seeks monthly GLP-1 - Fierce Biotech

1. Novo 'wishes Pfizer luck' with Metsera drug, seeks monthly GLP-1  Fierce Biotech
2. Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial  CNBC
3. Pfizer Beats Sales Estimates on Demand for Older Drugs  Bloomberg.com

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan  BioPharma Dive

Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off - The Motley Fool

Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off  The Motley Fool

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand - The Wall Street Journal

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand  The Wall Street Journal

Pfizer shares dip as vaccines continue to weigh on sales - Financial Times

Pfizer shares dip as vaccines continue to weigh on sales  Financial Times

Pharma stocks slump as Pfizer and Merck report earnings - qz.com

Pharma stocks slump as Pfizer and Merck report earnings  qz.com

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most - MarketBeat

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most  MarketBeat

A 'game of inches': Pfizer channels Al Pacino in World Cancer Day ad - Fierce Pharma

A 'game of inches': Pfizer channels Al Pacino in World Cancer Day ad  Fierce Pharma

Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks

Pfizer and BioNTech Pause modRNA Shingles Ambitions  TipRanks

Is Pfizer (PFE) Pricing Reflect Its Prospects After Reshaping Portfolio And Covid Outlook? - Yaho...

Is Pfizer (PFE) Pricing Reflect Its Prospects After Reshaping Portfolio And Covid Outlook?  Yahoo Finance

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans - B...

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans  Business Wire

Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial - Clinical Trials A...

Pfizer’s acquired monthly weight loss drug meets endpoints in Phase IIb trial  Clinical Trials Arena

Pfizer moves forward with its hopes for a monthly obesity drug - statnews.com

Pfizer moves forward with its hopes for a monthly obesity drug  statnews.com

Pfizer weight-loss drug data raises questions about side effects, shares fall - Reuters

Pfizer weight-loss drug data raises questions about side effects, shares fall  Reuters

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study - Fierce Biotech

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study  Fierce Biotech

Pfizer Hympavzi label expansion under FDA review (PFE:NYSE) - Seeking Alpha

Pfizer Hympavzi label expansion under FDA review (PFE:NYSE)  Seeking Alpha

Hiding in Plain Sight: The Racial Toll of Lyme Disease - pfizer.com

Hiding in Plain Sight: The Racial Toll of Lyme Disease  pfizer.com

Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street. - Barron's

Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street.  Barron's

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook - CNBC

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook  CNBC

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial - Reuters

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial  Reuters

Pfizer defends data on Metsera candidate - statnews.com

Pfizer defends data on Metsera candidate  statnews.com

Why Pfizer Stock Dropped Today - The Motley Fool

Why Pfizer Stock Dropped Today  The Motley Fool

Pfizer dips on new data for obesity drug acquired in $10B deal - BioPharma Dive

Pfizer dips on new data for obesity drug acquired in $10B deal  BioPharma Dive

Pfizer’s Obesity Bet PF-3944 Advances As Shares Screen Undervalued - Yahoo Finance

Pfizer’s Obesity Bet PF-3944 Advances As Shares Screen Undervalued  Yahoo Finance

Pfizer Q4 Earnings Call Highlights - Yahoo Finance

Pfizer Q4 Earnings Call Highlights  Yahoo Finance

Pfizer unveils data on Metsera drug - statnews.com

Pfizer unveils data on Metsera drug  statnews.com

Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? - Investor's Business Daily

Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly?  Investor's Business Daily

Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative - Morning...

Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative  Morningstar Canada

Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impa...

Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges  Fierce Biotech

Jim Cramer Expresses Concern About Pfizer Despite Its “Terrific Yield” - Yahoo Finance

Jim Cramer Expresses Concern About Pfizer Despite Its “Terrific Yield”  Yahoo Finance

Pfizer 4Q Results - Contract Pharma

Pfizer 4Q Results  Contract Pharma

Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story - Yahoo Finance

Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story  Yahoo Finance

Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss - Ya...

Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss  Yahoo Finance

Pfizer sets sights on R&D strategy amid modest FY25 results - Pharmaceutical Technology

Pfizer sets sights on R&D strategy amid modest FY25 results  Pharmaceutical Technology

How Pfizer’s CEO wielded moral clarity to help his team do the impossible - Fortune

How Pfizer’s CEO wielded moral clarity to help his team do the impossible  Fortune

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthl...

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial  Business Wire

Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story - Yahoo Finance

Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story  Yahoo Finance

Pfizer launches TrumpRx program offering up to 85% discount on medicines - Investing.com

Pfizer launches TrumpRx program offering up to 85% discount on medicines  Investing.com

Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data - Yahoo Finance

Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data  Yahoo Finance

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? - The Motley Fool

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?  The Motley Fool

Pfizer hemophilia drug could become first non-factor option for kids 6-11 - stocktitan.net

Pfizer hemophilia drug could become first non-factor option for kids 6-11  stocktitan.net

Sanofi sanctioned over CEO’s ‘bold claims’ about Pfizer vaccine - Fierce Pharma

Sanofi sanctioned over CEO’s ‘bold claims’ about Pfizer vaccine  Fierce Pharma

Skipping the Super Bowl, Pfizer unveils new cancer campaign that still nods to sports - MM+M - Me...

Skipping the Super Bowl, Pfizer unveils new cancer campaign that still nods to sports - MM+M  Medical Marketing and Media

Friday Five – Lilly flexes as Novo flinches, AstraZeneca goes big in obesity, Pfizer fine tunes…a...

Friday Five – Lilly flexes as Novo flinches, AstraZeneca goes big in obesity, Pfizer fine tunes…and more  FirstWord Pharma

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b - Fierce Biotech

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b  Fierce Biotech

Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more - CNBC

Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more  CNBC

Pfizer obesity drug shows weight loss but side effects cause dropouts - The Journal Record

Pfizer obesity drug shows weight loss but side effects cause dropouts  The Journal Record

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance - Business Wire

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance  Business Wire

Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs - BioSpace

Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs  BioSpace

Pfizer CEO addresses growing competition in weight-loss drugs - Fox Business

Pfizer CEO addresses growing competition in weight-loss drugs  Fox Business

Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’ - BioSpace

Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’  BioSpace

Spotlight On: Pfizer signals patience as the virtue it needs from investors - FirstWord Pharma

Spotlight On: Pfizer signals patience as the virtue it needs from investors  FirstWord Pharma

Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow - Yahoo Finance

Earnings To Watch: Pfizer (PFE) Reports Q4 Results Tomorrow  Yahoo Finance

Pfizer posts fourth-quarter beat, but takes $4.4B write-down - FirstWord Pharma

Pfizer posts fourth-quarter beat, but takes $4.4B write-down  FirstWord Pharma

3 Headwinds Facing Pfizer in 2026 - The Motley Fool

3 Headwinds Facing Pfizer in 2026  The Motley Fool

Pfizer Receives US FDA Priority Review for Expanded Hemophilia Treatment Use - marketscreener.com

Pfizer Receives US FDA Priority Review for Expanded Hemophilia Treatment Use  marketscreener.com

Pfizer’s Early Metsera Data Leaves Analysts Wanting More - BioSpace

Pfizer’s Early Metsera Data Leaves Analysts Wanting More  BioSpace

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance - Yahoo Finance

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance  Yahoo Finance

Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative - Morning...

Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative  Morningstar Canada

Pfizer: Messy Q4 Earnings Mask An Improving Business (NYSE:PFE) - Seeking Alpha

Pfizer: Messy Q4 Earnings Mask An Improving Business (NYSE:PFE)  Seeking Alpha

Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO - Yahoo Finance

Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO  Yahoo Finance

Pfizer beats fourth-quarter profit estimates on strong drug demand - Yahoo Finance

Pfizer beats fourth-quarter profit estimates on strong drug demand  Yahoo Finance

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? - Nasdaq

Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?  Nasdaq

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025 - Yahoo Finance

Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q4 CY2025  Yahoo Finance

Pfizer makes case for monthly maintenance dosing of obesity therapy - FirstWord Pharma

Pfizer makes case for monthly maintenance dosing of obesity therapy  FirstWord Pharma

Pfizer stock falls after solid earnings. What’s troubling Wall Street? - MSN

Pfizer stock falls after solid earnings. What’s troubling Wall Street?  MSN

Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms - Precisio...

Pfizer Reports 9 Percent Increase in Q4 Oncology Revenue as Ibrance Patent Cliff Looms  Precision Medicine Online

Pharmalittle: We're reading about a Pfizer obesity pill, Florida's failed drug importation plan, ...

Pharmalittle: We're reading about a Pfizer obesity pill, Florida's failed drug importation plan, and more  statnews.com

Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure - Yahoo Finance

Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure  Yahoo Finance

Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity - MedC...

Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity  MedCity News

Pfizer cuts prices up to 85% on 30+ drugs via TrumpRx and GoodRx - stocktitan.net

Pfizer cuts prices up to 85% on 30+ drugs via TrumpRx and GoodRx  stocktitan.net

Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates  Yahoo Finance

Pfizer’s stock fell after mixed response to weight-loss data for drug set to compete with Lilly’s...

Pfizer’s stock fell after mixed response to weight-loss data for drug set to compete with Lilly’s Zepbound  MarketWatch

Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag? - Endpoints News

Updated: Do Pfizer’s monthly GLP-1 data justify Metsera’s $10B price tag?  Endpoints News

Revenue falls for Pfizer while non-COVID growth offsets decline - The Pharma Letter

Revenue falls for Pfizer while non-COVID growth offsets decline  The Pharma Letter

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings - Endpoin...

One cancer drug steps back, and obesity asset steps forward, as Pfizer reports earnings  Endpoints News

Novo Nordisk: Pfizer weight loss drug offers credible new competition - Yahoo Finance

Novo Nordisk: Pfizer weight loss drug offers credible new competition  Yahoo Finance

Pfizer stock faces a Friday test after TrumpRx discounts hit the tape - TechStock²

Pfizer stock faces a Friday test after TrumpRx discounts hit the tape  TechStock²

Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care - BioSpace

Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care  BioSpace

Pfizer takes small step toward obesity market, but investors question limited trial results - Cra...

Pfizer takes small step toward obesity market, but investors question limited trial results  Crain's New York Business

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever (NYSE:PFE) - Seeki...

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever (NYSE:PFE)  Seeking Alpha

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot - Gizmodo

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot  Gizmodo

Pfizer Q4 earnings preview: All eyes on pipeline as blockbusters near patent cliff (PFE:NYSE) - S...

Pfizer Q4 earnings preview: All eyes on pipeline as blockbusters near patent cliff (PFE:NYSE)  Seeking Alpha

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook - Tech...

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook  TechStock²

Pfizer (PFE) Q4 2024 Earnings Call Transcript - AOL.com

Pfizer (PFE) Q4 2024 Earnings Call Transcript  AOL.com

Assessing Pfizer (PFE) Valuation After Recent Share Price Rebound And Oncology Expansion - Yahoo ...

Assessing Pfizer (PFE) Valuation After Recent Share Price Rebound And Oncology Expansion  Yahoo Finance

Pfizer’s ultra-long-acting injectable GLP-1 RA shows robust weight loss - The Pharma Letter

Pfizer’s ultra-long-acting injectable GLP-1 RA shows robust weight loss  The Pharma Letter

Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity - Citeline News & Insights

Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity  Citeline News & Insights

Pfizer stock dips on Metsera mid-stage trial results - Axios

Pfizer stock dips on Metsera mid-stage trial results  Axios

Pfizer beats Q4 estimates, releases mid-stage GLP-1 trial results, and maintains guidance for ful...

Pfizer beats Q4 estimates, releases mid-stage GLP-1 trial results, and maintains guidance for full-year 2026  Sherwood News

Pfizer probes slimming drug data from Metsera acquisition - medwatch.com

Pfizer probes slimming drug data from Metsera acquisition  medwatch.com

Pfizer Stock Drops on Obesity-Drug Study Data - The Wall Street Journal

Pfizer Stock Drops on Obesity-Drug Study Data  The Wall Street Journal

Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans - m...

Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans  marketscreener.com

March 27th Options Now Available For Pfizer (PFE) - Nasdaq

March 27th Options Now Available For Pfizer (PFE)  Nasdaq

The Administration’s War on Drug Development - National Review

The Administration’s War on Drug Development  National Review

Earnings call transcript: Pfizer’s Q4 2025 earnings surpass expectations, stock dips - Investing.com

Earnings call transcript: Pfizer’s Q4 2025 earnings surpass expectations, stock dips  Investing.com

Pfizer Gets FDA Priority Review for Expanded Hympavzi Approval - 富途牛牛

Pfizer Gets FDA Priority Review for Expanded Hympavzi Approval  富途牛牛

Pfizer stock slips after Q4 2025 results (PFE:NYSE) - Seeking Alpha

Pfizer stock slips after Q4 2025 results (PFE:NYSE)  Seeking Alpha